To discover new bioactive lead compounds for medicinal purposes, 2-cyano-3-(4-substituted)-N-(quinolin-3-yl) acrylamide derivatives 2-24, chromenes 25, 26 and benzochromenes 27, 28 were synthesized. The structures of the newly synthesized compounds were confi rmed by elemental analyses, IR, 1 H NMR and 13 C NMR spectroscopies. In addition, the structure of compound 1 was confi rmed through X-ray crystallography. All the newly synthesized compounds were evaluated for their cytotoxic activity against the breast cancer cell line MCF7. The corresponding , resp. Also, quinoline acrylamides containing 2,3,4-trimethoxyphenyl 17, 2-chlorophenyl 10, benzo[d][1,3]dioxol 12, 2-methoxynaphthalen 22, 2,4-dichlorophenyl 18 and quinoline carrying a chromene-3-carboxamide moiety 25 were nearly as active as doxorubicin, while quinoline acrylamides incorporating unsubstituted phenyl 2, p-tolyl 3, 2,4-dienamide 8, 3-nitrophenyl 13, 4-nitrophenyl 14, 3,4-dimethoxyphenyl 16 and chromene 26 exhibited a moderate activity. In addition, quinoline with acetamide 1, 4-hydroxyphenyl 4, 4-dimethylaminophenyl 9, 4-chlorophenyl 11, 3-bromophenyl 20, 4-bromophenyl 21 and 3-thienyl moiety 24 showed less activity than doxorubicin. On the other hand, quinoline having 2-methoxyphenyl 5, 4-methoxyphenyl 6, 4-metho xynaph thalene 23 and chromene-2-carboxamide 28 showed no activity.
Anti-breast cancer activity of some novel quinoline derivatives
To discover new bioactive lead compounds for medicinal purposes, 2-cyano-3-(4-substituted)-N-(quinolin-3-yl) acrylamide derivatives 2-24, chromenes 25, 26 and benzochromenes 27, 28 were synthesized. The structures of the newly synthesized compounds were confi rmed by elemental analyses, IR, 1 H NMR and 13 C NMR spectroscopies. In addition, the structure of compound 1 was confi rmed through X-ray crystallography. All the newly synthesized compounds were evaluated for their cytotoxic activity against the breast cancer cell line MCF7. The corresponding 2-cyano-3-(4-hydroxy-3-methoxyphenyl)-N-(quinolin-3-yl) acrylamide (15), 3-oxo-N-(quinolin-3-yl)-3H-benzol[f ] chromene-2-carboxamide (27), 2-cyano-3-(4-fl uorophenyl-N-(quinolin-3-yl) acrylamide (7), 2-cyano-5-(4-(di meth ylamino) phenyl)-N-(quinolin-3-yl) penta-2,4-dienamide (19) , resp. Also, quinoline acrylamides containing 2,3,4-trimethoxyphenyl 17, 2-chlorophenyl 10, benzo[d] [1, 3] dioxol 12, 2-methoxynaphthalen 22, 2,4-dichlorophenyl 18 and quinoline carrying a chromene-3-carboxamide moiety 25 were nearly as active as doxorubicin, while quinoline acrylamides incorporating unsubstituted phenyl 2, p-tolyl 3, 2,4-dienamide 8, 3-nitrophenyl 13, 4-nitrophenyl 14, 3,4-dimethoxyphenyl 16 and chromene 26 exhibited a moderate activity. In addition, quinoline with acetamide 1, 4-hydroxyphenyl 4, 4-dimethylaminophenyl 9, 4-chlorophenyl 11, 3-bromophenyl 20, 4-bromophenyl 21 and 3-thienyl moiety 24 showed less activity than doxorubicin. On the other hand, quinoline havSeveral quinoline derivatives, isolated from natural sources or prepared synthetically, are important for medicinal chemistry and biomedical use. The bark of Cinchona plant containing quinine has been utilized to treat palpitations (1), fevers and tertians for more than 200 years. Quinidine, a diastereo isomer of quinine, was regarded in the early 20 th century as the most potent antiarrhythmic compound isolated from the Cinchona plant (2) . The quinoline skeleton is oft en used to design many synthetic compounds with diverse pharmacological properties, such as anti-infl ammatory (3), antimicrobial (4), cytotoxic (5), antibacterial (6) and antitumor activity (7) . In addition, quinoline derivatives fi nd use in the synthesis of fungicides, virucides, biocides, alkaloids and fl avoring agents (8, 9) . Quinolines also act as carbonic anhydrase inhibitors (10, 11) . On the other hand, various fused systems of quinolines were studied for their intercalative DNA binding properties. A literature survey reveals that the antitumor activity is due to the intercalation between the base pairs of DNA and interferences with the normal functioning of enzyme topoisomerase II, which is involved in the breaking and releasing of DNA strands (12) . The antitumor drugs that intercalate DNA are of growing interest in the fi eld of anticancer derivatives. On the other hand, doxorubicin, the reference drug used in this study, is a drug used in cancer chemotherapy. It is an anthracycline antibiotic and works by intercalating DNA and inhibiting of macromolecular biosynthesis. This inhibits the progression of the enzyme topoisomerase II, which relaxes super coils in DNA for transcription. Doxorubicin stabilizes the topoisomerase II complex aft er it has broken the DNA chain for replication, preventing the DNA double helix from being resealed and thereby stopping the process of replication. It is commonly used in the treatment of a wide range of cancers such as acute leukemia Hodgkin's disease and other lymphomas and cancers of the breast, adrenal cortex, endometrial, lung, ovary, and other sites. As a part of our ongoing research program directed towards developing new approaches to a variety of heterocyclic ring systems for anticancer activity, especially those containing nitrogen compounds (13-21), we herein report the utility of strategic starting material 3-aminoquinoline for the synthesis of target compounds.
EXPERIMENTAL
Melting points (uncorrected) were determined in an open capillary in a Gallenkamp melting point apparatus (Sanyo Gallenkamp, UK). Precoated silica gel plates (Kieselgel 0.25 mm, 60 F254, Merck, Germany) were used for thin layer chromatography. A developing solvent system of chloroform/methanol (8:2) was used and the spots were detected by ultraviolet light. IR spectra (KBr disc) were recorded using an FT-IR spectrophotometer (Perkin Elmer, USA). 1 H NMR spectra were scanned on a NMR spectrophotometer (Bruker AXS Inc., Switzerland), operating at 500 MHz for 1 H-and 125.76 MHz for 13 C NMR. Chemical shift s are expressed in d values (ppm) relative to TMS as an internal standard, using DMSO-d 6 as a solvent. Elemental analyses were done on a model 2400 CHNSO analyser (Perkin Elmer, USA). All values were within ±0.4 % of the theoretical values. All reagents used were of AR grade. The starting material 3-aminoquinoline was purchased from Sigma (USA) and was directly used for the preparation of target compounds. (Table I) .
-A mixture of 1 (2.11 g, 0.01 mol) and appropriate aldehyde (0.01 mol) in absolute ethanol (20 mL) containing 3 drops of piperidine was refl uxed for 8 h. The reaction mixture was cooled and poured into ice/water. The solid obtained was recrystallized from dioxane to give quinoline derivatives 2-24, respectively (Table I) .
General procedure for 2-oxo-N-(quinolin-3-yl)-2H-chromene-3-carboxamide (25) and 3-oxo-
chromene-2-carboxamide (27) -To a solution of 1 (2.11 g, 0.01 mol) in acetic anhydride (20 mL), salicylaldehyde (1.22 g, 0.01 mol) or 2-hydroxy-1-naphthaldehyde (1.72 g, 0.01 mol) and fused sodium acetate (0.8 g, 0.01 mol) were added. The reaction mixture was refl uxed for 2 h, cooled and the solid was fi ltered and crystallized from ethanol to give 25 and 27, respectively (Table I) .
General procedure for 2-imino-N-(quinolin-3-yl)-2H-chromene-3-carboxamide (26) and 3-imino-N-(quinolin-3-yl)-3H-benzol[f]chromene-2-carboxamide (28) -
A mixture of compound 1 (2.11 g, 0.01 mol), salicylaldehyde (1.22 g, 0.01 mol) or 2-hydroxy-1-naphthyladehyde (1.72 g, 0.01 mol) and anhydrous ammonium acetate (1.15 g, 0.015 mol) was refl uxed in absolute ethanol (30 mL) for 2 h. The obtained solid was recrystallized from ethanol to give 27 and 29, respectively (Table I ).
In vitro anti-breast cancer activity
In vitro cytotoxic activity of the synthesized compounds was measured using the sulforhodamine B stain (SRB) assay aft er the method of Skehan (22) . The human breast cancer cell line MCF7 was obtained from the National Cancer Institute (Cairo, Egypt). The cell lines were grown in RPMI 1640 medium containing 10 % fetal bovine serum (Lonza, Switzerland), 100 IU mL -1 penicillin, 100 mg mL -1 streptomycin and 2 mmol L -1 L-glutamine (Sigma, USA). Cells were plated in 96-multiwell plates (10 4 cells/well). Aft er cell inoculation, the micro titer plates were incubated at 37 °C in 5 % CO 2 , 95 % air and 100 % relative humidity for 24 h prior to addition of experimental drugs to allow att achment of cells to the plate wall. Aft er 24 h, cell line was fi xed in situ with TCA (trichloroacetic acid).
Test compounds were dissolved in DMSO and diluted with saline to the appropriate volume and maintained in RPMI 1640 medium. Diff erent concentrations of each test compound (5, 12.5, 25 and 50 μmol L -1 ) were added to the cell monolayer. Triplicate wells were prepared for each individual dose. Monolayer cells were incubated with the compound(s) for 48 h at 37 °C and in an atmosphere of 5 % CO 2 . Aft er 48 h, cells were fi xed in situ by gentle addition of 50 μL of cold 30 % (m/V) TCA (fi nal concentration, 10 % TCA) and incubated for 60 min at 4 °C. The supernatant was discarded; the plates were washed fi ve times with tap water and air dried. Sulforhodamine B solution (50 μL) at 0.4 % (m/V) in 1 % acetic acid was added to each of the wells and plates were incubated for 20 min at room temperature. Aft er staining, unbound dye was removed by four washes with 1 % acetic acid and the att ached stain was recovered with Tris-EDTA buff er. Color intensity was measured using an ELISA reader (BMG Labtech, Germany). The relation between the surviving fraction and drug concentration was plott ed to get the survival curve for the breast cancer cell line (MCF7) aft er specifi ed time (22) . The molar concentration required for 50 % inhibition of cell viability (IC 50 ) was calculated from the constructed dose-response curve using Prism soft ware (Graphpad, Inc., USA) and compared with the reference drug doxorubicin. Results are given in Table III .
RESULTS AND DISCUSSION

Chemistry
The designed target compounds are depicted in Schemes 1 and 2. In the present investigation, the strategic starting material, 2-cyano-N-(quinolin-3-yl) acetamide (1), was H NMR and 13 C NMR spectral data. In addition, the structure of compound 1 was confi rmed by X-ray crystallography (23) . IR spectrum showed characteristic bands at 3260 cm -1 (NH), 2201 cm -1 (C≡N), 1700 cm -1 (C=O), 1617 cm -1 (C=N).
1 H NMR spectrum of 1 reveled signals at 4.0 ppm assigned to the CH 2 group, 7.5 and 8.6 ppm due to 2CH quinoline, 10.8 ppm corresponding to the NH group. 13 C NMR spectrum of 1 exhibited a singlet at 161.9 ppm for (C=O) (Table II) . Also, a novel series of potentially active quinoline incorporating cyanoacrylamide moieties (tyrphostin analogs) 2-24 were synthesized through reaction of compound 1 with various aldehydes in absolute ethanol containing a catalytic amount of piperidine (Scheme 1). The structures of compounds 2-24 were established on the basis of elemental analyses and spectral data. IR spectra revealed the presence of characteristic bands at 3426-3189 cm -1 (NH), 2222-2170 cm -1 (C≡N), 1700-1657 cm -1 (C=O).
1 H NMR spectra of compounds 2-24 revealed the presence of a singlet at 9.0-8.0 ppm assigned to CH group and 11.1-10.0 ppm for NH group. Furthermore, Perkin reaction (24) was carried out by reaction of salicylaldehyde and/or 2-hydroxy-1-naphthaldehyde in acetic anhydride in the presence of sodium acetate to give the corresponding chromene-2-one 25 and benzochromene-2-one 27, while conducting the same reaction in ethanol containing ammonium acetate furnished 2-iminochromene 26 and 2-iminobenzochromene 28 (Scheme 2). The structure of compounds 25-28 was supported of elemental analyses and spectral data. IR spectrum of 25 revealed bands at 3217 cm -1 (NH), 1711, 1668 cm -1 (2C=O). H NMR spectrum showed a singlet at 12.6 ppm corresponding to the imino group (Table II) . 
In vitro anti-breast cancer activity
The relationship between the surviving fraction and drug concentration was plott ed; the response parameter calculated was IC 50 value, which corresponds to the compound concentration that causes 50 % inhibition of cellular viability (Table III) . From Table III we can see that the tested compounds 15, 27, 7, 19 were found to be more potent than doxorubicin as reference drug (IC 50 = 47.9 μmol L MCF7. These results att ract att ention due to the possible use of the newly synthesized acrylamide derivatives carrying 4-hydroxy-3-methoxyphenyl (15), benzochromene-2-one (27) and acrylamide bearing 4-fl uorophenyl (7) and styrylphenyl (10) for treatment of breast tumors.
CONCLUSIONS
In this work, we report the synthesis of a novel series of quinolines bearing a biologically active acrylamide 1-24, chromene-2-one 25, chromene-2-imino 26, benzochromene--2-one 27 and benzochromene-2-imino 28 moieties through simple and convenient routes. The new derivatives were evaluated for their anticancer activity against a human tumor breast cancer cell line (MCF7). It was found that the most potent compounds in this study were the corresponding 2-cyano-3-(4-hydroxy-3-methoxyphenyl)-N-(quinolin-3-yl) acrylamide (15), 3-oxo-N-(quinolin-3-yl)-3H-benzol[f]chromene-2-carboxamide (27), 2-cyano-3-(4-fl uorophenyl-N-(quinolin-3-yl) acrylamide (7), 2-cyano-5-(4-(dimethylamino) phenyl)-N-(quinolin-3-yl) penta-2,4-dienamide (19) compared to doxorubicin as a positive control.
